5 Proven GLP-1 Health Benefits Beyond Weight Loss

By Coach Jim O'Connor

Most people start a GLP-1 medication for one reason: to lose weight. Some also take it to manage blood sugar. But a growing body of large, randomized clinical trials published in the New England Journal of Medicine suggests these medications may affect several other areas of health.

This article reviews five of those trials. It explains what each one measured, who was studied, what the results showed, and where the evidence still has limits. Those limits matter. Each trial enrolled a specific population, so the benefits do not automatically apply to everyone taking these drugs.

Why Some Benefits May Not Depend on Weight Loss

GLP-1 receptors are found in many tissues beyond the gut and pancreas, including the heart, blood vessels, kidneys, liver, and brain. That is one reason researchers are studying effects beyond appetite and glucose control.

Several trials found benefits that were not fully explained by the amount of weight lost. Researchers have proposed anti-inflammatory and direct organ effects as possible explanations, but these mechanisms are still being studied. Treat them as hypotheses, not established facts.

1. Heart Protection: The SELECT Trial

The SELECT trial enrolled 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes. Participants received either semaglutide (2.4 mg weekly) or placebo. Results were published in the New England Journal of Medicine in 2023.

Semaglutide reduced the risk of major adverse cardiovascular events, which include heart attack, stroke, and cardiovascular death, by about 20 percent compared with placebo.

Who this applies to: Adults with existing heart disease and overweight or obesity. The trial did not study people without cardiovascular disease for this outcome.

2. Kidney Protection: The FLOW Trial

The FLOW trial studied adults with type 2 diabetes and chronic kidney disease. Researchers tracked whether semaglutide could slow kidney decline and reduce deaths from kidney or cardiovascular causes. The trial was published in the New England Journal of Medicine in 2024.

Semaglutide reduced the composite kidney outcome, which included kidney failure, a sustained drop in kidney function, and death from kidney or cardiovascular causes, by about 24 percent. The trial was stopped early after an independent monitoring committee found the benefit clear enough that continuing to withhold it from the control group was no longer appropriate.

Who this applies to: Adults with type 2 diabetes and chronic kidney disease. Kidney disease often causes no symptoms until it is advanced, so routine kidney testing matters for anyone with diabetes or high blood pressure.

3. Liver Health: The ESSENCE Trial

Metabolic dysfunction-associated steatohepatitis, or MASH, is a serious form of fatty liver disease involving liver inflammation and, in some people, scarring. Many people with MASH have no symptoms. Treatment options have been limited.

The ESSENCE trial enrolled adults with biopsy-confirmed MASH and fibrosis. In the phase 3 results published in the New England Journal of Medicine, semaglutide resolved MASH without worsening fibrosis in 62.9 percent of participants, compared with 34.3 percent on placebo.

Who this applies to: Adults with biopsy-confirmed MASH. A liver biopsy or specialized imaging is needed to diagnose it, which is why anyone with elevated liver enzymes or fatty liver on imaging should discuss it with their physician.

4. Joint Pain: The STEP 9 Trial

Knee osteoarthritis is one of the most common causes of chronic pain and reduced mobility in adults over 40. The STEP 9 trial, published in the New England Journal of Medicine in 2024, studied adults with obesity and knee osteoarthritis.

Participants taking semaglutide reported significantly greater reductions in knee pain and improvements in physical function than those on placebo.

Researchers are still working out how much of the benefit came from lower body weight and how much from direct effects on joint inflammation. Either way, reduced pain can make resistance training more achievable, and resistance training is one of the most effective long-term treatments for knee osteoarthritis.

Who this applies to: Adults with obesity and knee osteoarthritis.

5. Sleep Apnea: The SURMOUNT-OSA Trials

Obstructive sleep apnea is a condition in which the airway repeatedly collapses during sleep. It is common in adults with obesity, and standard treatment has been continuous positive airway pressure (CPAP), a nightly mask machine.

The two SURMOUNT-OSA trials, published in the New England Journal of Medicine in 2024, tested tirzepatide in adults with moderate-to-severe sleep apnea and obesity. Over 52 weeks, tirzepatide reduced the apnea-hypopnea index, which counts breathing pauses and shallow breaths per hour of sleep, by about 25 to 29 events per hour. Placebo produced reductions of about 5 events per hour.

Roughly 43 percent of participants in the trial that did not use CPAP reached remission or mild, non-symptomatic sleep apnea, compared with about 14 percent on placebo.

Important limit: Roughly half of participants still had clinically significant apnea after a year. Tirzepatide is not a replacement for CPAP for most people. Do not stop CPAP without a new sleep study and guidance from your sleep physician.

Who this applies to: Adults with moderate-to-severe sleep apnea and obesity.

What the Evidence Does Not Yet Show

These five trials are strong evidence for the specific outcomes they measured. They do not establish several things.

Long-term effects beyond the trial periods are still being studied. Most of these trials ran between one and four years. Benefits for people without the specific condition studied in each trial are not established. Cost, side effects, and individual health history all matter in deciding whether a medication is appropriate. And none of this changes the need for medical supervision.

What This Means for People Taking GLP-1 Medications

If you are taking a GLP-1 medication, these findings are a reason to talk with your physician about your full health picture, not only your weight. Ask whether the medication is relevant to your heart, kidney, liver, joint, or sleep health, and whether you should be monitored for any of them.

The findings also highlight something important about muscle. Weight loss from these medications can include lean tissue. Resistance training and adequate protein help preserve muscle, which supports mobility, metabolic health, and the ability to keep moving through a joint problem. The medication may create better conditions for training, and training helps protect what the medication does not directly build.

Frequently Asked Questions

Do GLP-1 medications protect the heart?
The SELECT trial found about a 20 percent reduction in major cardiovascular events in adults with overweight or obesity and existing heart disease. That is a specific population. It is not a general statement about everyone taking these drugs.

Can GLP-1 medications treat fatty liver disease? The ESSENCE trial found that semaglutide resolved MASH in a larger share of participants than placebo. The trial studied adults with biopsy-confirmed MASH. Anyone concerned about fatty liver should be evaluated by a physician.

Can tirzepatide replace CPAP for sleep apnea? No, not for most people. Tirzepatide significantly reduced apnea severity, but roughly half of participants still had clinically significant apnea after a year. Never stop CPAP without a sleep study and physician guidance.

Are these benefits guaranteed? No. Trial results describe average outcomes in study populations. Individual results vary, and the benefits depend on the condition being treated.

What should I do before starting or continuing a GLP-1 medication? Discuss your full health history with a qualified physician, including heart, kidney, liver, sleep, and joint health. Ask about monitoring and whether your situation matches the populations studied.

Take the Next Step

Want to see how your current nutrition, training, and recovery support your long-term health while taking a GLP-1 medication? Start with the free tools below.

Take the Free GLP-1 Assessment: Three minutes to see where you stand and which change will have the biggest impact.

Download the GLP-1 Optimization Blueprint: A free framework for protecting muscle, metabolism, and healthy function.

Explore the GLP-1 Optimization Resource Hub: Evidence-based guides and tools in one place.

Jim O'Connor is an exercise physiologist and certified nutrition coach with 37 years of experience helping professionals in Los Angeles build lasting strength and metabolic health. This article is educational and does not replace medical advice. Talk with your physician before starting, stopping, or changing any medication.

Medical Disclaimer

The information in this article is for educational purposes only. It is not medical advice, and it does not replace consultation with a qualified healthcare provider. The trials discussed enrolled specific populations, and results describe average outcomes in those groups, not guaranteed outcomes for any individual. Benefits observed in one condition, such as heart or kidney disease, may not apply to people without that condition.

Do not start, stop, or change any medication, including GLP-1 medications, based on this article. Talk with your physician about whether a treatment is appropriate for you, and about your full medical history. If you have symptoms such as chest pain, sudden vision changes, shortness of breath, or severe abdominal pain, seek emergency care right away.

Jim O’Connor is an exercise physiologist and certified nutrition coach. He is not a physician, and nothing in this article establishes a doctor-patient relationship.

Referenced

Get All Of my GLP-1 Optimization Resources (100% fREE)

Click Here For Access To All Of My GLP-1 Optimization Resources
Posted in GLP-1 Optimization and tagged , , , , , ,